Get started
Author

P. Haluska

Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma
2008 · D. Olmos, S. Okuno, et al. · Journal of Clinical Oncology · 41
Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without letrozole in aromatase inhibitor-resistant breast cancer.
2011 · P. Haluska, A. Dhar, et al. · Journal of Clinical Oncology · 12
Phase I trial of Intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in recurrent ovarian cancer (OvCa)
2008 · E. Galanis, L. C. Hartmann, et al. · Journal of Clinical Oncology · 9
Population pharmacokinetics of CP-751,871, a monoclonal antibody against IGF-I receptor, in patients with multiple myeloma or solid tumors
2008 · D. Yin, M. L. Paccagnella, et al. · Journal of Clinical Oncology · 8
Massives lokalisiertes Lymphödem einer extrem fettleibigen Patientin
2002 · J. Váňa, K. Adamicová, et al. · Der Chirurg · 6
Abstract PD3-4: A first-in-human phase I study of the tamoxifen (TAM) metabolite, Z-endoxifen hydrochloride (Z-Endx) in women with aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) (NCT01327781)
2013 · MP Goetz, VA Suman, et al. · Cancer Research · 5
388 POSTER Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma
2008 · S. Postel-Vinay, S. Okuno, et al. · European Journal of Cancer Supplements · 5
[Massive localized lymphedema: a reactive lesion simulating liposarcoma (case report].
2002 · K Adamicová, J Vána, et al. · PubMed · 4
P2-11-11: IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors.
2011 · MA Becker, X Hou, et al. · Cancer Research · 2
3LB MEDI-573, a dual IGF-1/-2 neutralizing antibody, blocks IGF-1R and IR-A signaling and maintains glucose homeostasis in a Phase 1 study for advanced solid tumors
2010 · M. Menefee, P. LoRusso, et al. · European Journal of Cancer Supplements · 2
HER receptor signaling confers resistance to IGF-1R targeted therapy
2008 · P. Haluska, J. M. Carboni, et al. · Journal of Clinical Oncology · 1
Comparison of MISR2 expression in patient and successive passages of patient-derived xenografts of ovarian cancer
2015 · S. Gill, Q. Zhang, et al. · Gynecologic Oncology
609 A Phase 1 Study of MEDI-573, an Investigational Monoclonal Antibody That Targets IGF-I and IGF-II: Safety, Pharmacokinetics, and Antitumor Activity in Adults with Advanced Solid Tumors
2012 · P. Haluska, M.E. Menefee, et al. · European Journal of Cancer
P01-4 Antitumor effect of ridaforolimus (MK-8669) in combination with dalotuzumab (MK-0646) and aromatase inhibitor letrozole in a postmenopausal breast cancer model
2012 · X. Hou, B. Haines, et al. · Growth Hormone & IGF Research
P03-11 Quantifying insulin receptor isoform expression in FFPE breast tumors
2012 · S. Harrington, S.J. Weroha, et al. · Growth Hormone & IGF Research
PD01-06: Endoxifen Exhibits Potent Anti-Tumor Activity and Regulates Different Genes Than Tamoxifen in an Aromatase Expressing MCF7 Model Resistant to Letrozole.
2011 · M Goetz, X Hou, et al. · Cancer Research
P-01 HER receptor signaling confers resistance to the insulin-like growth factor 1 receptor inhibitor, BMS-536924
2008 · P. Haluska, J.M. Carboni, et al. · Growth Hormone & IGF Research
OR12,1 Bi-directional resistance pathways relevant to anti-IGF-1R targeted therapy: pathway to clinical development
2008 · P. Haluska · Growth Hormone & IGF Research
Works count: 18
Citation count: 95
H-index: 5
I10-index: 2
Year
Topic
Type